Photo via South China Morning Post

US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious

Read the original at South China Morning Post ↗
Cite

Shen, X. (2026, September 24). US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious. South China Morning Post. https://www.scmp.com/business/companies/article/3368665/us-regulators-back-multi-cancer-blood-test-hong-kong-doctors-remain-cautious?utm_source=rss_feed

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

South China Morning Post · collected 2026-09-24 · by Xinmei Shen

Quick Summary

US regulators have shown support for a new multi-cancer early detection blood test called the "Galleri test" developed by US company Grail. The FDA panel voted to recommend premarket approval for this test, which detects cancer in healthy individuals through circulating tumour DNA analysis. However, Hong Kong doctors are expressing caution and emphasize the need for more data before endorsing its widespread use.
Written by AI on 2026-09-24, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

On Thursday, a US Food and Drug Administration (FDA) panel voted in favor of Grail’s “Galleri test,” recommending it for premarket approval. This decision marks a significant milestone in the development of multi-cancer early detection (MCED) blood tests, which aim to identify signs of cancer in asymptomatic individuals by analyzing circulating tumor DNA (ctDNA) and other abnormal molecules in bodily fluids like blood and urine. However, Hong Kong doctors have expressed caution about the test, emphasizing the need for more data before widespread adoption. Despite this, there is growing interest in using a single blood sample to detect multiple types of cancer early on.

Written for “Cancer Blood Test Regulation Differences” on 2026-11-04, grounded in this article and the 0 other(s) covering the same event.

Story

📰 Cancer Blood Test Regulation Differences
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
3
sentences that state something as happening or true
Uncertain
0%
0 of 3 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
62/100
South China Morning Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-24 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

South China Morning Post · 3740 article(s) · 8 correction(s) detected
Running correction rate · 8 correction(s)
2026-11-03
Singapore hit-and-run: organiser of fund for orphaned boy vows transparency
2026-11-01
Former Apple Daily publisher joins mainland China tour for rehabilitated offenders
2026-10-16
Nobel Peace Prize: the message behind Navi Pillay’s win
2026-10-16
Indonesian governor’s Singapore trip adds fury to forest fire, haze crisis
2026-10-04
Flight to Okinawa diverts back to Hong Kong after suspected landing gear fault
2026-10-04
Tennessee prisons chief resigning after botched execution of Christa Pike
2026-09-29
Indonesian prison chief suspended over secret VIP compound for inmates
2026-09-28
Trump ‘arms offer’ to China jolts Washington into moves to contain the fallout

Who wrote this

Xinmei Shen
12 article(s) here · 0 carrying a prediction
🔮 Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.
2026-09-26 · assertive framing · China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
2026-09-23 · speculative framing · Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
Also by Xinmei Shen
Tokenised gold bar to advance Hong Kong’s ambitions as digital, metal trading hub
2026-11-03 · South China Morning Post
How Hong Kong’s fintech strategy is progressing – and where growth still lags
2026-11-02 · South China Morning Post
Chinese drug sector’s stature grows at major cancer conference
2026-10-28 · South China Morning Post
Former HSBC executive launches wealth platform powered by team of AI agents
2026-10-12 · South China Morning Post
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 12 articles by Xinmei Shen →

Topics

FDA Food and Drug Administration Grail Hong Kong

Subjects

FDA ORG · 1× Food and Drug Administration ORG · 1× Grail ORG · 1× Hong Kong GPE · 1×

Narrative

Doctors say more data is needed despite growing interest in detecting multiple cancers from a single blood sample In a landmark decision for the emerging field of multi-cancer early detection (MCED) blood tests, a US Food and Drug Administration (FDA) panel on Thursday voted in favour of US company Grail’s “Galleri test”, recommending it for premarket approval.
framing: assertive · carried by 1 article(s) · first seen 2026-09-24
2026-09-24 · South China Morning Post
US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious · assertive framing

Claims (3 extracted, 0 hedged)

US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious asserted
doctors → back → test
Doctors say more data is needed despite growing interest in detecting multiple cancers from a single blood sample In a landmark decision for the emerging field of multi-cancer early detection (MCED) blood tests, a US Food and Drug Administration (FDA) panel on Thursday voted in favour of US company Grail’s “Galleri test”, recommending it for premarket approval. asserted
panel → say → approval
MCED tests seek to identify signs of cancer in healthy, asymptomatic individuals by analysing abnormal molecules, including circulating tumour DNA (ctDNA), in bodily fluids such as blood and urine. asserted
tests → seek → blood
💬Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

🕘History 🎫Support
Terms · Privacy · beta v2.0.0
Articles to 4 Nov 2026